In studies conducted in our country, by Yordam et al (14) and Kurnaz et al (15), FAH-SDS was reported to be -2.06 and -1.8 respectively, in patients with IGHD who received GH therapy with similar duration and treatment doses (Table 3). The gene discussed is GH1; the disease is isolated congenital growth hormone deficiency.